Aquatic ecosystems in Byers Peninsula, Livingston Island. An Antarctic Noah’s Ark in a changing world

第6回極域科学シンポジウム[OB] 極域生物圏11月17日（火）　統計数理研究所 セミナー室1（D305

Effects of inorganic selenium injection on the performance of beef cows and their subsequent calves

Sixty-seven pregnant Angus cows and their subsequent calves were used in a randomized design to evaluate the effect of inorganic Se injection from 80 d of gestation until weaning on cow reproductive parameters, BW and BCS evolution, milk yield and quality, calf growth and calf hematology parameters. The treatments were as follows: 1) Se+: cows were administered Se as sodium selenite at doses of 0.05 mg/Kg of BW at 80, 140, 200, 260 d of gestation and 30, 90, 150 and 240 d of lactation. Calves from Se + cows were Se as sodium selenite subcutaneously injected with a dose of 0.05 mg/Kg of BW at 70, 104, 144 d of age; 2) Control: cows and calves were administered sterile NaCl solution (9 g/l) at the same volume and intervals as Se + treatment. At the start of the experiment, forage Se concentration was 58.6 ppb ± 7.6 ppb, and cow whole blood Se concentration was similar (P > 0.10) between treatments (Se+, 29.3 ± 0.3 ppb; Control, 28.1 ± 0.5 ppb). After Se injection, cow whole blood Se concentration was increased (P  0.10) between treatments at d 70 after birth. After the first Se injection (70 d of age), calf whole blood Se concentration was increased (P  0.10) between treatments throughout the experiment. Ovarian follicle diameter measured by ultrasound 47 d postpartum was greater (P = 0.03) in Se + cows compared to Control cows. Pregnancy rate to fixed time artificial insemination (FTAI), overall pregnancy rate (P > 0.10) and pregnancy loss (P = 0.19) did not differ between groups. Selenium injection did not affect (P > 0.10) milk yield and composition. Calf morphometric parameters, BW at birth and growth rate during lactation were not affected (P > 0.10) by treatments. No significant effect (P > 0.10) was observed between treatments on hematological results of blood samples from calves at weaning. Results of this study shown that inorganic Se injection was an efficient tool to improve Se-status in cow-calf operation under extensive management. Selenium injection increased follicle diameter in postpartum beef cow, however, did not affect the rest of the variables studied.EEA Cuenca del SaladoFil: Rodriguez, Alejandro Martin. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Cuenca del Salado; ArgentinaFil: Lopez Valiente, Sebastian. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Cuenca del Salado; ArgentinaFil: Brambilla, Emilio Cesar. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Balcarce; ArgentinaFil: Fernandez, Eduardo Luján. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Balcarce; ArgentinaFil: Maresca, Sebastian. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Cuenca del Salado; Argentin

Subcutaneous anti-COVID-19 hyperimmune immunoglobulin for prevention of disease in asymptomatic individuals with SARS-CoV-2 infection: a double-blind, placebo-controlled, randomised clinical trialResearch in context

Summary: Background: Anti-COVID-19 hyperimmune immunoglobulin (hIG) can provide standardized and controlled antibody content. Data from controlled clinical trials using hIG for the prevention or treatment of COVID-19 outpatients have not been reported. We assessed the safety and efficacy of subcutaneous anti-COVID-19 hyperimmune immunoglobulin 20% (C19-IG20%) compared to placebo in preventing development of symptomatic COVID-19 in asymptomatic individuals with SARS-CoV-2 infection. Methods: We did a multicentre, randomized, double-blind, placebo-controlled trial, in asymptomatic unvaccinated adults (≥18 years of age) with confirmed SARS-CoV-2 infection within 5 days between April 28 and December 27, 2021. Participants were randomly assigned (1:1:1) to receive a blinded subcutaneous infusion of 10 mL with 1 g or 2 g of C19-IG20%, or an equivalent volume of saline as placebo. The primary endpoint was the proportion of participants who remained asymptomatic through day 14 after infusion. Secondary endpoints included the proportion of individuals who required oxygen supplementation, any medically attended visit, hospitalisation, or ICU, and viral load reduction and viral clearance in nasopharyngeal swabs. Safety was assessed as the proportion of patients with adverse events. The trial was terminated early due to a lack of potential benefit in the target population in a planned interim analysis conducted in December 2021. ClinicalTrials.gov registry: NCT04847141. Findings: 461 individuals (mean age 39.6 years [SD 12.8]) were randomized and received the intervention within a mean of 3.1 (SD 1.27) days from a positive SARS-CoV-2 test. In the prespecified modified intention-to-treat analysis that included only participants who received a subcutaneous infusion, the primary outcome occurred in 59.9% (91/152) of participants receiving 1 g C19-IG20%, 64.7% (99/153) receiving 2 g, and 63.5% (99/156) receiving placebo (difference in proportions 1 g C19-IG20% vs. placebo, −3.6%; 95% CI -14.6% to 7.3%, p = 0.53; 2 g C19-IG20% vs placebo, 1.1%; −9.6% to 11.9%, p = 0.85). None of the secondary clinical efficacy endpoints or virological endpoints were significantly different between study groups. Adverse event rate was similar between groups, and no severe or life-threatening adverse events related to investigational product infusion were reported. Interpretation: Our findings suggested that administration of subcutaneous human hyperimmune immunoglobulin C19-IG20% to asymptomatic individuals with SARS-CoV-2 infection was safe but did not prevent development of symptomatic COVID-19. Funding: Grifols